Akero Therapeutics to Present at the Evercore ISI 4th Annual HealthCONx Virtual Conference

Rhea-AI Summary

Akero Therapeutics (Nasdaq: AKRO) announced its participation in the Evercore ISI 4th Annual HealthCONx Virtual Conference on December 2 at 3:30 p.m. E.T. This event will include a management fireside chat, which will be accessible via a live webcast on the company's investor relations page. Akero Therapeutics focuses on developing treatments for serious metabolic diseases, specifically targeting non-alcoholic steatohepatitis (NASH). Its lead candidate, efruxifermin (EFX), is currently undergoing two Phase 2b trials aimed at assessing its effectiveness in various patient groups.

SOUTH SAN FRANCISCO, Nov. 26, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will participate in a fireside chat at the Evercore ISI 4^th Annual HealthCONx Virtual Conference on Thursday December 2 at 3:30 p.m. E.T.

A live webcast of the Company fireside chat will be available through the investor relations section of the Company's website at www.akerotx.com. Following the live webcasts, archived replays will be available on the Company's website.

About Akero Therapeutics
Akero Therapeutics is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Akero's lead product candidate, efruxifermin (EFX), is a differentiated Fc-FGF21 fusion protein that has been engineered to mimic the balanced biological activity profile of native FGF21, an endogenous hormone that alleviates cellular stress and regulates metabolism throughout the body. EFX is designed to offer convenient once-weekly subcutaneous dosing. The consistency and magnitude of observed effects position EFX to be a potentially best-in-class medicine, if approved, for treatment of NASH. EFX is currently being evaluated in two Phase 2b clinical trials: the HARMONY study in pre-cirrhotic patients with F2/F3 fibrosis and the SYMMETRY study in compensated cirrhotic (F4) patients. Akero is headquartered in South San Francisco. Visit us at www.akerotx.com for more information.

Investor Contact:
Christina Tartaglia
Stern Investor Relations, Inc.
212.362.1200
christina.tartaglia@sternir.com

Media Contact:
650.487.6488
media@akerotx.com

FAQ

When is Akero Therapeutics participating in the Evercore ISI 4th Annual HealthCONx Conference?

Akero Therapeutics will participate in the Evercore ISI 4th Annual HealthCONx Conference on December 2 at 3:30 p.m. E.T.

How can I watch the Akero Therapeutics fireside chat?

The fireside chat can be watched live through the investor relations section of Akero Therapeutics' website.

What is the focus of Akero Therapeutics?

Akero Therapeutics focuses on developing transformational treatments for serious metabolic diseases, particularly non-alcoholic steatohepatitis (NASH).

What is efruxifermin (EFX) in relation to Akero Therapeutics?

Efruxifermin (EFX) is Akero Therapeutics' lead product candidate, designed to treat NASH with potential once-weekly subcutaneous dosing.

What clinical trials are being conducted by Akero Therapeutics?

Akero Therapeutics is conducting two Phase 2b clinical trials: the HARMONY study for pre-cirrhotic patients and the SYMMETRY study for compensated cirrhotic patients.